Zealand Pharma Gross Margin 2017-2024 | ZLDPF

Zealand Pharma gross margin for the quarter ending June 30, 2024 was 92.45%.

  • Zealand Pharma average gross margin for 2023 was 97.99%, a 21.5% decline from 2022.
  • Zealand Pharma average gross margin for 2022 was 80.65%, a 37.84% increase from 2021.
  • Zealand Pharma average gross margin for 2021 was 58.51%, a 31.26% increase from 2020.

Gross margin can be defined as a company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage.

Zealand Pharma Gross Margin 2017-2024 | ZLDPF

  • Zealand Pharma average gross margin for 2023 was 97.99%, a 21.5% decline from 2022.
  • Zealand Pharma average gross margin for 2022 was 80.65%, a 37.84% increase from 2021.
  • Zealand Pharma average gross margin for 2021 was 58.51%, a 31.26% increase from 2020.

Gross margin can be defined as a company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.8B
Vertex Pharmaceuticals (VRTX)$117.5B
Regeneron Pharmaceuticals (REGN)$111.6B
Bristol Myers Squibb (BMY)$109.4B
Gilead Sciences (GILD)$105.3B
CSL (CSLLY)$95.7B
GSK (GSK)$80.5B
Alnylam Pharmaceuticals (ALNY)$34.4B
Argenex SE (ARGX)$31.7B
BioNTech SE (BNTX)$29.2B
Biogen (BIIB)$27B
BeiGene (BGNE)$23.9B
Moderna (MRNA)$23.1B
Illumina (ILMN)$22.5B
Genmab (GMAB)$15.5B
BioMarin Pharmaceutical (BMRN)$13.2B
Incyte (INCY)$13B
Exact Sciences (EXAS)$12.6B
Vaxcyte (PCVX)$12.4B
Insmed (INSM)$12.4B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.5B
QIAGEN (QGEN)$9.9B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$8.9B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$8.3B
Revolution Medicines (RVMD)$7.9B
Intra-Cellular Therapies (ITCI)$7.7B
Repligen (RGEN)$7.7B